Arbutus Biopharma Corp (ABUS)
2.985
+0.10
(+3.29%)
USD |
NASDAQ |
May 17, 16:00
2.985
0.00 (0.00%)
After-Hours: 20:00
Arbutus Biopharma Revenue (Quarterly): 1.532M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 1.532M |
December 31, 2023 | 2.145M |
September 30, 2023 | 4.658M |
June 30, 2023 | 4.651M |
March 31, 2023 | 6.687M |
December 31, 2022 | 6.245M |
September 30, 2022 | 5.952M |
June 30, 2022 | 14.24M |
March 31, 2022 | 12.58M |
December 31, 2021 | 3.206M |
September 30, 2021 | 3.34M |
June 30, 2021 | 2.329M |
March 31, 2021 | 2.113M |
December 31, 2020 | 2.386M |
September 30, 2020 | 1.523M |
June 30, 2020 | 1.514M |
March 31, 2020 | 1.491M |
December 31, 2019 | 1.618M |
September 30, 2019 | 3.061M |
June 30, 2019 | 0.653M |
March 31, 2019 | 0.679M |
December 31, 2018 | 1.678M |
September 30, 2018 | 1.587M |
June 30, 2018 | 1.244M |
March 31, 2018 | 1.436M |
Date | Value |
---|---|
December 31, 2017 | 2.534M |
September 30, 2017 | 6.892M |
June 30, 2017 | 1.039M |
March 31, 2017 | 0.235M |
December 31, 2016 | -0.195M |
September 30, 2016 | 0.774M |
June 30, 2016 | 0.309M |
March 31, 2016 | 0.603M |
December 31, 2015 | 11.09M |
September 30, 2015 | 4.065M |
June 30, 2015 | 3.44M |
March 31, 2015 | 4.682M |
December 31, 2014 | 4.35M |
September 30, 2014 | 4.362M |
June 30, 2014 | 1.811M |
March 31, 2014 | 4.43M |
December 31, 2013 | 7.527M |
September 30, 2013 | 2.963M |
June 30, 2013 | 2.844M |
March 31, 2013 | 2.132M |
December 31, 2012 | 3.709M |
September 30, 2012 | 3.097M |
June 30, 2012 | 3.559M |
March 31, 2012 | 3.572M |
December 31, 2011 | 4.369M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.653M
Minimum
Jun 2019
14.24M
Maximum
Jun 2022
4.096M
Average
2.724M
Median
Revenue (Quarterly) Benchmarks
Moderna Inc | 167.00M |
Dentsply Sirona Inc | 953.00M |
Pacira BioSciences Inc | 167.12M |
Chimerix Inc | -- |
Karyopharm Therapeutics Inc | 33.13M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -17.88M |
Total Expenses (Quarterly) | 20.72M |
EPS Diluted (Quarterly) | -0.10 |
Enterprise Value | 416.15M |
Profit Margin (Quarterly) | -1.17K% |
Earnings Yield | -14.74% |
Normalized Earnings Yield | -14.75 |